Publications

Search or filter publications

Search publications Search

Filter by type:

Filter by publication type

• Book
• Book chapter
• Conference paper
• Journal article
• Other
• Patent
• Poster
• Report
• Scholarly edition
• Software
• Thesis dissertation
• Working paper

Filter by year:

Filter from 20262025202420232022202120202019201820172016201520142013201220112010200920082007200620052004200320022001200019991998199719961995199419931992199119901989198819871986198519841983198219811980197919781977197619751974197319721971197019691968 to Filter to 20262025202420232022202120202019201820172016201520142013201220112010200920082007200620052004200320022001200019991998199719961995199419931992199119901989198819871986198519841983198219811980197919781977197619751974197319721971197019691968

---

Search results

• Journal article
  Sun M, Ye B, Zhao Y, Ledesma-Amaro R, Eshboev F, Gao AX, Wang Pet al., 2026,

  5'-End Translationalization: Iterative Assembly of Leaderless Polycistronic Amplifiers for Context-Independent Expression in the Food-Grade Bacterium Corynebacterium glutamicum.

  , J Agric Food Chem, Vol: 74, Pages: 19859-19870

  Corynebacterium glutamicum is a crucial food-grade (GRAS) bacterial chassis widely utilized for the industrial production of amino acids and nutraceuticals. However, the efficient production of recombinant proteins and secondary metabolites in this host remains limited by context dependence and low translational efficiency. To overcome this, we introduce a 5'-end translationalization strategy. By repurposing passive 5' untranslated regions (5'UTRs) into actively translated fore-cistrons, we converted conventional monocistronic designs into context-independent, leaderless polycistronic designs (PCDs). This assembly of concatenated fore-cistrons functions as a translational amplifier, largely decoupling protein output from mRNA abundance. We validated this platform by optimizing two biomanufacturing paradigms: achieving a 4.07-fold enhanced secretion of OmlA, a porcine vaccine antigen, and boosting biosynthesis of the food-grade pigment indigoidine to 1.20 g/L (a 7.33-fold increase over baselines). Together, this framework establishes a versatile, portable toolkit to overcome translational bottlenecks, enabling robust hyperproduction of recombinant proteins and engineered metabolites in biotechnology.

  • Abstract
  • Author Web Link
  • Cite
• Journal article
  Downey DG, Schulze I, Eich A, Singh D, Larbig M, Vit O, Nicolas LB, Chotirmall SH, Chalmers JDet al., 2026,

  Safety and antimicrobial efficacy of CSL787, a novel nebulized IgG therapy, in patients with bronchiectasis: results from a randomized phase 1 trial.

  , Am J Respir Crit Care Med, Vol: 212, Pages: 1643-1646
  • Author Web Link
  • Cite
• Journal article
  Chen H, Peng H, Ellis T, Ledesma Amaro Ret al., 2026,

  Programmable cell–cell adhesion in synthetic yeast communities for improved bioproduction

  , Nature Chemical Biology, Vol: 22, Pages: 1057-1066, ISSN: 1552-4450

  In multicellular systems, engineering-controlled cell–cell adhesion and metabolic interdependence are vital for developing complex functionalities. This study introduces a yeast synthetic toolbox for modular cell–cell adhesion and cocultures, aiming to overcome the limitations of existing approaches that lack genetic specificity and control. First, a model yeast strain 007Δ is created with seven main flocculation and agglutination genes removed, providing a clean background for synthetic adhesion systems. Then, three distinct adhesion pair systems—Strategy 1, Strategy 2.1 and Strategy 2.2—are established involving yeast flocculation and agglutination proteins and yeast surface display systems. In addition, a quantitative assessment is conducted on the adhesive specificity and strength, alongside the capability of synthetic adhesion to generate patterns. Finally, we successfully demonstrate enhanced bioproduction of the high-value food antioxidant, resveratrol, utilizing synthetic cocultures coupled with cell adhesion systems. We anticipate that this toolkit will emerge as a valuable resource for diverse applications in synthetic biology and biomanufacturing.

  • Abstract
  • Publisher Web Link
  • Cite
• Journal article
  Majumdar A, Kotta-Loizou I, Buck M, Roychowdhury Tet al., 2026,

  Temperature-dependent biofilm and sublancin production arrest soil arsenic and antibiotic resistance gene mobility

  , Journal of Hazardous Materials, Vol: 512, ISSN: 0304-3894

  Climate change-induced warming and arsenic soil contamination synergistically threaten agricultural sustainability by restructuring microbial communities and accelerating antimicrobial resistance dissemination. Here, through integrated greenhouse and field trials, we demonstrate that Bacillus subtilis 168-derived biofilm and sublancin, a glycosylated antimicrobial peptide, simultaneously immobilise rhizospheric arsenic and suppress horizontal transfer of antibiotic resistance genes (ARGs). Temperature-dependent biofilm formation (25–35°C) enhanced arsenic sequestration within the extracellular polymeric substance matrix, with SEM-EDX revealing a 74% increase in arsenic weight percentage at 35°C and ToF-SIMS confirming ∼14-fold and ∼9-fold increases in root-associated arsenic on biofilm-colonised surfaces in greenhouse and field trials, respectively. Sublancin production peaked at 30°C (129.72 mg L⁻¹), selectively suppressing all 12 tested pathogenic Gram-positive species by 74–86% while preserving Gram-negative communities. Bio-amendment reduced horizontal gene transfer frequency by 74.7% (p < 0.001) across all temperature regimes. Transcriptomic profiling revealed coordinated upregulation of exopolysaccharide biosynthesis (FDR ∼1.0 × 10⁻²⁷) and sublancin machinery (sunA: +3.5 log₂), alongside downregulation of conventional ARGs (vanA, blaTEM: −2.5 to −4.0 log₂). These findings establish sublancin as a dual-function, climate-adaptive soil bio-amendment simultaneously addressing arsenic bioaccumulation and antibiotic resistance gene dissemination under warming scenarios.

  • Abstract
  • Publisher Web Link
  • Cite
• Journal article
  Odenkirk MT, Chaparro JM, Montgomery NT, Leaptrot KL, Sherrod SD, May JC, van Eekelen H, Schipper B, Chaura J, Velez GE, Chathiran W, Michel CR, Doenges KA, Reisdorph R, Maeda-Yamamoto M, Valdiviez L, Keshet U, Wells J, Mackell S, Bell D, Tapia Leiva S, Partridge S, Rago D, Ahonen L, Ito Y, Read ML, Evans JC, Gruszczynski MJ, Szalach L, Boyko SC, Watkins S, Ledesma Amaro R, Fiehn O, Reisdorph N, Srichamnong W, Jaramillo-Botero A, de Vos RCH, Hall RD, McLean JA, Broeckling CD, Prenni JEet al., 2026,

  Correction to “Multi-laboratory assessment reveals variable ion species profiles in electrospray ionization mass spectrometer”

  , Journal of the American Society for Mass Spectrometry, Vol: 37, Pages: 1683-1684, ISSN: 1044-0305

  We are requesting a correction of inaccurate author affiliations. Specifically, the correct affiliation for Juliana Chaura, Gabriel Esteban Velez, and Andres Jaramillo-Botero should be iÓMICAS Research Institute, Pontificia Universidad Javeriana, Cali 760031, ColombiaThe correct author list and affiliations are shown in the Author Information with this Correction.

  • Abstract
  • Publisher Web Link
  • Cite
• Journal article
  Chin D, Hernandez-Beeftink T, Donoghue L, Guillen-Guio B, Leavy OC, Adegunsoye A, Booth HL, CleanUP-IPF Investigators of the Pulmonary Trials Cooperative, Fahy WA, Fingerlin TE, Gooptu B, Hall IP, Hart SP, Hill MR, Hirani N, Johnson SR, Kaminski N, Lorenzo-Salazar JM, Ma S-F, McAnulty RJ, McCarthy MI, Stockwell AD, Maher TM, Millar AB, Molyneaux PL, Molina-Molina M, Navaratnam V, Neighbors M, Oldham JM, Parfrey H, Saini G, Sayers I, Sheng XR, Stewart ID, Strek ME, Tobin MD, Whyte MKB, Zarcone MC, Zhang Y, Martinez F, Yaspan BL, Reynolds CJ, Schwartz DA, Flores C, Noth I, Jenkins RG, Allen RJ, Wain LVet al., 2026,

  Genome-wide association study of idiopathic pulmonary fibrosis susceptibility using clinically curated European ancestry datasets.

  , Eur Respir J, Vol: 68

  New association signals suggest a potentially causal role for the gene encoding KL-6, a known biomarker of fibrosis, and implicate genes involved in angiogenesis in IPF development https://bit.ly/3Ocr01s

  • Abstract
  • Author Web Link
  • Cite
• Journal article
  Hull RC, Liu Y, Cao Z, Xuan KTL, de Lima Headley DA, Richardson H, Hennayake C, Lind H, McIntosh E, Pollock J, Hughes C, Viligorska K, Choi H, Gao Y, Chotirmall SH, Shoemark A, Robertson K, Burgel P-R, Vendrell M, Xu X, Qu J-M, Song Y, Guan W-J, Chen R, Singh S, Talwar D, Mohan BVM, Tripathi SK, Swarnakar R, Trivedi S, Goeminne PC, Shteinberg M, De Soyza A, Altenburg J, Haworth CS, Sibila O, Polverino E, Loebinger MR, Ringshausen FC, Mertsch P, Lorent N, Dimakou K, Mendez R, Mclaughlin AM, Borrill Z, Lord R, Finch S, Blasi F, Burr L, Crisafulli M, Keating R, Middleton PG, Long MB, Aliberti S, Morgan L, Dhar R, Chalmers JD, Xu J-F, EMBARC, EMBARC India, Australian bronchiectasis registry and BE-Chinaet al., 2026,

  Comorbid diabetes disease severity and microbial changes in patients with bronchiectasis: a combined analysis of data from the EMBARC, EMBARC-India, Australian, and BE-China registries.

  , Lancet Respir Med, Vol: 14, Pages: 620-632

  BACKGROUND: Bronchiectasis and diabetes commonly coexist and are associated with immune dysfunction and increased susceptibility to infection. Although diabetes is associated with worse prognosis in cystic fibrosis-related bronchiectasis, data are scarce for its impact on non-cystic fibrosis bronchiectasis. This study aimed to characterise the impact of diabetes on clinical outcomes and microbial and inflammatory profiles in patients with bronchiectasis. METHODS: This analysis comprised data from the European Bronchiectasis Registry (EMBARC), Respiratory Research Network of India (EMBARC-India), Chinese Bronchiectasis Registry (BE-China), and Australian Bronchiectasis Registry (ABR); 30 263 patients with CT-confirmed bronchiectasis in 33 countries were included in the analysis: 16 963 from EMBARC (Jan 12, 2015, to April 12, 2022), 2361 from EMBARC-India plus additional Asian countries (June 1, 2015, to Sept 1, 2017), 10 324 from BE-China (Jan 10, 2020, to March 31, 2024), and 615 from the ABR (March 7, 2016, to Sept 11, 2018). Clinical data were compared between patients with and without diabetes. Long-term outcome data were available in EMBARC and EMBARC-India. Microbiome and inflammatory profiles were characterised in a sub-cohort of EMBARC patients by sputum 16S rRNA sequencing (n=433) and serum Olink (n=479). FINDINGS: 2487 (8·2%) of 30 263 patients with bronchiectasis had diabetes. Patients with diabetes had a higher prevalence of comorbidities than those without diabetes, including cardiovascular disorders (53·5% vs 21·8%, p<0·0001), asthma (27·5% vs 21·0%, p<0·0001), and chronic obstructive pulmonary disease (34·3% vs 19·0%, p<0·0001). Patients with diabetes had more severe disease than those without diabetes, with higher Bronchiectasis Severity Index scores (8 [IQR 5-12] vs 7 [4-10], p<0·0001) and UK Medical Research Council (MRC) dyspnoea scores (p<0·0001) and

  • Abstract
  • Author Web Link
  • Cite
• Journal article
  De Boeck K, Burgel P-R, Bierlaagh M, Hill K, Amaral M, Birimberg-Schwartz L, Brewington JJ, Davies JC, Karadag B, Martin U, Mense M, Pedemonte N, Sharma N, Tayor-Cousar JL, Sermet I, Beekman JMet al., 2026,

  ECFS statement on theratyping and theranostics in the context of rare and ultrarare CFTR variants in people with CF.

  , J Cyst Fibros, Vol: 25, Pages: 584-593

  Genotype-based drug development has yielded highly effective therapies, notably the triple combinations elexacaftor/tezacaftor/ivacaftor (ETI) and vanzacaftor/tezacaftor/deutivacaftor (VTD), now approved in Europe for people with CF having at least one non-class I variant. However not all these people with CF will respond to ETI or VTD, and a few not under the label may respond. Facilitating opportunities to access for patients with rare variants has required a shift in paradigm toward functional testing-based access. This approach assesses the potential benefit of modulator therapy using in vitro functional assays, either in engineered systems expressing defined CFTR variants (theratyping) or in patient-derived tissues (theranostics). We review theranostics as a critical tool for personalized medicine in CF, highlighting its validation in in vitro models derived from patients' own cells such as human intestinal organoids and human nasal epithelial cells. We discuss the current regulatory landscape regarding modulator approval and propose strategies for improving equitable access to effective treatments for all people with CF. Importantly, we advocate for functional assays to be accepted as standalone evidence of drug efficacy for patients with rare variants. Theranostic approaches remain critical when theratyping has not been achieved, and genetic data is not available or clearly interpretable. Indeed, theranostics has emerged as an essential pillar of CF drug access, complementing genotype-driven strategies. As the field advances, continued validation, standardization, and regulatory integration of in vitro functional assays will be key to ensuring that every person with CF-regardless of their genotype-has the opportunity to benefit from precision therapies.

  • Abstract
  • Author Web Link
  • Cite
• Journal article
  Qi C, Wang C, Jiang Y, Ledesma-Amaro R, Wang Q, Wang Let al., 2026,

  Genome-Based Identification and Characterization of two Bacteriocins Produced by Lactiplantibacillus Plantarum BL25 in Beef.

  , Probiotics Antimicrob Proteins, Vol: 18, Pages: 7759-7777
  • Author Web Link
  • Cite
• Journal article
  Hernandez-Beeftink T, Allen RJ, Leavy OC, Cuthbertson L, Molyneaux PL, Wain LVet al., 2026,

  Genes, gut microbiome and lungs: untangling the web of idiopathic pulmonary fibrosis.

  , ERJ Open Res, Vol: 12, ISSN: 2312-0541

  This work highlights the use of genetics to explore potential causal links between the gut microbiome and IPF, underscoring the importance of integrating gut and lung microbiome data with host genetics to better understand IPF mechanisms https://bit.ly/4bdzf4V.

  • Abstract
  • Author Web Link
  • Cite

This data is extracted from the Web of Science and reproduced under a licence from Thomson Reuters. You may not copy or re-distribute this data in whole or in part without the written consent of the Science business of Thomson Reuters.